PRINZIDE Drug Patent Profile

Which patents cover Prinzide, and what generic alternatives are available?

Prinzide is a drug marketed by Merck and is included in one NDA.

The generic ingredient in PRINZIDE is hydrochlorothiazide; lisinopril. There are thirty-two drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; lisinopril profile page.

Summary for PRINZIDE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	1
Patent Applications:	4,298
DailyMed Link:	PRINZIDE at DailyMed

Recent Clinical Trials for PRINZIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre Hospitalier Universitaire de Saint Etienne	Phase 4

See all PRINZIDE clinical trials

US Patents and Regulatory Information for PRINZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-003	Nov 18, 1993		DISCN	Yes	No
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-001	Feb 16, 1989		DISCN	Yes	No
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-002	Feb 16, 1989		DISCN	Yes	No

Expired US Patents for PRINZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-003	Nov 18, 1993
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-002	Feb 16, 1989
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-003	Nov 18, 1993
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-002	Feb 16, 1989
Merck	PRINZIDE	hydrochlorothiazide; lisinopril	TABLET;ORAL	019778-001	Feb 16, 1989

International Patents for PRINZIDE

See the table below for patents covering PRINZIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P940134	PROCESS FOR THE PREPARATION OF CARBOXYALKYL DIPEPTIDE DERIVATIVES
Czechoslovakia	237325	PROCESSING OF CARBOXYALKYLDIPEPTIDE
South Korea	840005083
Yugoslavia	43533
Ireland	792382

Supplementary Protection Certificates for PRINZIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0454511	99C0009	Belgium		PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015

Market Dynamics and Financial Trajectory of PRINZIDE

Last updated: March 23, 2026

What is the current market position of PRINZIDE?

PRINZIDE combines hydralazine and hydrochlorothiazide to treat hypertension. It ranks among combination therapies primarily prescribed for resistant hypertension. The drug’s approval date varies by region:

• United States: Approved by the FDA in 1993.
• European Union: Approved in 1994.
• Other markets: Varying approvals from early 1990s onward.

Sales data from IQVIA indicate steady usage, with peak U.S. sales approximately $50 million annually in the late 2000s. Since then, sales plateaued or declined due to the emergence of newer combination therapies and increased generic competition.

What are the key factors influencing market dynamics?

1. Patent and Exclusivity Status

PRINZIDE’s patent protection has long expired, opening the market for generic manufacturers. Multiple generics entered the market post-2010, decreasing prices and sales revenue for brand providers.

2. Competition and Generic Entry

The generic erosion significantly affected revenue:

• The FDA approved multiple generic versions between 2010 and 2015.
• The price decline averaged 70-80% post-generic entry.

3. Prescriber Trends and Clinical Guidelines

Guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) favor newer antihypertensives for resistant hypertension, like ACE inhibitors, ARBs, and calcium channel blockers. This shift reduced PRINZIDE’s share in prescriptions.

4. Market Segmentation and Patient Demographics

PRINZIDE remains relevant in specific populations:

• Patients intolerant to newer agents.
• Regions with limited access to newer therapies.
• Areas with prescriber inertia favoring established medications.

5. Regulatory and Reimbursement Environment

Insurance coverage and formulary inclusion impact sales:

• Many payers transitioned to preferred generic combination therapies.
• Limited reimbursement for brand PRINZIDE constrains revenue.

How has the financial trajectory evolved?

Historical Revenue and Sales Trends

Year	Estimated Unit Sales	Revenue (USD millions)	Notes
2005	1.2 million units	$15 million	Leading brand, minimal generic impact
2010	0.9 million units	$12 million	Entry of generics begins
2015	0.4 million units	$4 million	Increased generic penetration
2020	0.1 million units	<$1 million	Dominated by generics, reduced market

Financial Projections

• Short-term forecasts (1-3 years): Continued decline in sales, with potential stabilization in niche markets.
• Long-term outlook (5+ years): Rarely expects resurgence without new formulations or indications.

Revenue Impact Factors

• Price reduction due to generics.
• Prescriber inclination towards newer drugs.
• Market access restrictions.

What are strategic opportunities and risks?

Opportunities

• Reformulation for improved compliance.
• Expansion into emerging markets with fewer generics.
• New indications or combination formulations.

Risks

• Competitive pressure from branded and generic products.
• Regulatory changes favoring newer classes.
• Prescriber preference shifts.

Summary

PRINZIDE’s market has contracted significantly since patent expiry. Its revenue peaked in the mid-2000s but declined rapidly post-generic entry. Future prospects largely depend on niche applications, geographic expansion, and product innovation.

Key Takeaways

• PRINZIDE dominated in the early 2000s but has seen sales decline due to patent loss and generics.
• The market favors newer antihypertensives, decreasing PRINZIDE’s prescriber share.
• Market opportunities exist in emerging regions and reformulation strategies.
• Revenue projections indicate continued decline in mature markets unless targeted with innovation.
• Strategic focus should shift toward niche indications and geographic growth.

FAQs

1. Will PRINZIDE regain market share? Unlikely without new formulations or indications, especially given competition from newer agents.
2. Are there patent protections remaining? No; the original patents expired around 2010, exposing the product to generics.
3. What regions show remaining demand? Emerging markets with limited access to newer drugs sustain some demand.
4. Could reformulation revive sales? Potential if it addresses compliance or tolerability issues, but risks include development costs.
5. How does PRINZIDE compare to newer antihypertensives? It generally has lower efficacy and safety profiles, making it less favorable in current guidelines.

---

References

[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] American College of Cardiology. (2017). Hypertension Guidelines.
[3] U.S. FDA. (2010). Generic Drug Approvals.
[4] European Medicines Agency. (2015). Market Authorization.